Abstract
Accumulating evidence supports the potential of proteasome inhibitors as immunosuppressants. Proteasome inhibitors interfere with antigen processing and presentation, as well as with the signaling cascades involved in immune cell function and survival. Both myeloma and healthy plasma cells appear to be highly susceptible to proteasome inhibitors due to impaired proteasomal activity in both cell types. As a consequence, these agents can be used to reduce antibody production and thus prevent antibody-induced tissue damage. Several clinical studies have explored the potential of bortezomib, a peptide boronate proteasome inhibitor, for treating immune disorders, such as antibody-mediated organ rejection and graft-versus-host disease (GVHD), with encouraging results. Here, we discuss the biological rationale for the use of proteasome inhibitors as immunosuppressive agents and review the clinical experience with bortezomib in immune-mediated diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 270-276 |
| Number of pages | 7 |
| Journal | Seminars in Hematology |
| Volume | 49 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jul 2012 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Proteasome Inhibitors as Immunosuppressants : Biological Rationale and Clinical Experience. / Moran, Eva; Carbone, Federico; Augusti, Valeria; Patrone, Franco; Ballestrero, Alberto; Nencioni, Alessio.
In: Seminars in Hematology, Vol. 49, No. 3, 07.2012, p. 270-276.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Proteasome Inhibitors as Immunosuppressants
T2 - Biological Rationale and Clinical Experience
AU - Moran, Eva
AU - Carbone, Federico
AU - Augusti, Valeria
AU - Patrone, Franco
AU - Ballestrero, Alberto
AU - Nencioni, Alessio
PY - 2012/7
Y1 - 2012/7
N2 - Accumulating evidence supports the potential of proteasome inhibitors as immunosuppressants. Proteasome inhibitors interfere with antigen processing and presentation, as well as with the signaling cascades involved in immune cell function and survival. Both myeloma and healthy plasma cells appear to be highly susceptible to proteasome inhibitors due to impaired proteasomal activity in both cell types. As a consequence, these agents can be used to reduce antibody production and thus prevent antibody-induced tissue damage. Several clinical studies have explored the potential of bortezomib, a peptide boronate proteasome inhibitor, for treating immune disorders, such as antibody-mediated organ rejection and graft-versus-host disease (GVHD), with encouraging results. Here, we discuss the biological rationale for the use of proteasome inhibitors as immunosuppressive agents and review the clinical experience with bortezomib in immune-mediated diseases.
AB - Accumulating evidence supports the potential of proteasome inhibitors as immunosuppressants. Proteasome inhibitors interfere with antigen processing and presentation, as well as with the signaling cascades involved in immune cell function and survival. Both myeloma and healthy plasma cells appear to be highly susceptible to proteasome inhibitors due to impaired proteasomal activity in both cell types. As a consequence, these agents can be used to reduce antibody production and thus prevent antibody-induced tissue damage. Several clinical studies have explored the potential of bortezomib, a peptide boronate proteasome inhibitor, for treating immune disorders, such as antibody-mediated organ rejection and graft-versus-host disease (GVHD), with encouraging results. Here, we discuss the biological rationale for the use of proteasome inhibitors as immunosuppressive agents and review the clinical experience with bortezomib in immune-mediated diseases.
UR - http://www.scopus.com/inward/record.url?scp=84862653224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862653224&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2012.04.004
DO - 10.1053/j.seminhematol.2012.04.004
M3 - Article
C2 - 22726551
AN - SCOPUS:84862653224
VL - 49
SP - 270
EP - 276
JO - Seminars in Hematology
JF - Seminars in Hematology
SN - 0037-1963
IS - 3
ER -